Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.

Patterson, Brandon J; Chen, Chi-Chang; McGuiness, Catherine B; Glasser, Lisa I; Sun, Kainan; Buck, Philip O

Patterson, Brandon J; Chen, Chi-Chang; McGuiness, Catherine B; Glasser, Lisa I; Sun, Kainan; Buck, Philip O.

Afiliação

Patterson BJ; US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission].
Chen CC; IQVIA, Pennsylvania, PA, USA.
McGuiness CB; IQVIA, Pennsylvania, PA, USA.
Glasser LI; US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission].
Sun K; IQVIA, Pennsylvania, PA, USA.
Buck PO; US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, USA [Employment at Initial Submission].

Hum Vaccin Immunother ; 17(8): 2482-2487, 2021 08 03.

Article em En | MEDLINE | ID: mdl-33849373

Assuntos

Vacina contra Herpes Zoster; Herpes Zoster; Adulto; Idoso; Herpes Zoster/prevenção & controle; Herpesvirus Humano 3; Humanos; Pessoa de Meia-Idade; Estados Unidos; Vacinas Sintéticas

Palavras-chave

Herpes zoster; immunization; postherpetic neuralgia; public health; recombinant zoster vaccine; shingles; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google